γ‐Secretase inhibitors in cancer clinical trials are pharmacologically and functionally distinct

γ‐Secretase inhibitors (GSIs) are being actively repurposed as cancer therapeutics based on the premise that inhibition of NOTCH1 signaling in select cancers is therapeutic. Using novel assays to probe effects of GSIs against a broader panel of substrates, we demonstrate that clinical GSIs are pharm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ran, Yong, Hossain, Fokhrul, Pannuti, Antonio, Lessard, Christian B, Ladd, Gabriela Z, Jung, Joo In, Minter, Lisa M, Osborne, Barbara A, Miele, Lucio, Golde, Todd E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494507/
https://www.ncbi.nlm.nih.gov/pubmed/28539479
http://dx.doi.org/10.15252/emmm.201607265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494507/
https://www.ncbi.nlm.nih.gov/pubmed/28539479
http://dx.doi.org/10.15252/emmm.201607265

Ejemplares similares